Mahukuntan kasar Sin, sun sanar da ba da umarnin cinikayyar nau’in farko na alluran rigakafin cutar numfashi ta COVID-19, wanda aka samar a cikin kasar bisa sharadi.
Rigakafin wanda hukumar lura da magunguna ta kasar Sin NMPA ta ba da umarnin cinikayyar sa, kamfanin Beijing Biological Products Institute ne ya samar da shi, wanda ke karkashin gungun kamfanonin “China National Biotec Group” ko CNBG, mai alaka da kamfanin Sinopharm.
Yayin wani taron manema labarai da majalisar gudanarwar kasar Sin ta kira, da hadin gwiwar cibiyar kandagarki da dakile yaduwar cutar COVID-19 ta kasar Sin, an tabbatar da cewa, sakamakon wucin gadi na gwaji a zagaye na 3 na rigakafin da aka yiwa mutane, ya shaida amfanin rigakafin ya kai kaso 79.34 bisa dari, wanda ya kai mizanin da WHO, da NMPA suka gindaya kafin fara amfani da ko wane nau’i na rigakafi. (Saminu)
